Oncology Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 91 articles
Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets
May 2026 FDA Oncology Actions: 8 Approvals Reshape the Landscape
Tip Sheet GLP-1s and Cancer: Key Insights for Pharma BD and Investors
Kairos Pharma Highlights CL-741 Acquisition and 2026 Clinical Milestones: A Strategic Analysis for Pharma Decision-Makers
Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
ASCO26: Gastrointestinal Cancers Enter the Limelight Amid Key Readout Surge
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
Pfizer sharpens prostate cancer case with Talzenna win — oncology
AstraZeneca's Camizestrant: Navigating Divergent Regulatory Paths for Breast Cancer Treatment
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
A Brief History of Major Events in Oncology
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer